Literature DB >> 27159645

The evolution of gadolinium based contrast agents: from single-modality to multi-modality.

Li Zhang1, Ruiqing Liu1, Hui Peng2, Penghui Li3, Zushun Xu1, Andrew K Whittaker2.   

Abstract

Gadolinium-based contrast agents are extensively used as magnetic resonance imaging (MRI) contrast agents due to their outstanding signal enhancement and ease of chemical modification. However, it is increasingly recognized that information obtained from single modal molecular imaging cannot satisfy the higher requirements on the efficiency and accuracy for clinical diagnosis and medical research, due to its limitation and default rooted in single molecular imaging technique itself. To compensate for the deficiencies of single function magnetic resonance imaging contrast agents, the combination of multi-modality imaging has turned to be the research hotpot in recent years. This review presents an overview on the recent developments of the functionalization of gadolinium-based contrast agents, and their application in biomedicine applications.

Entities:  

Year:  2016        PMID: 27159645     DOI: 10.1039/c6nr00267f

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  10 in total

1.  MnO nanoparticles with unique excitation-dependent fluorescence for multicolor cellular imaging and MR imaging of brain glioma.

Authors:  Junxin Lai; Tingjian Wang; Hao Wang; Fengqiang Shi; Wei Gu; Ling Ye
Journal:  Mikrochim Acta       Date:  2018-04-02       Impact factor: 5.833

2.  Water bridge coordination on the metal-rich facets of Gd2O3 nanoplates confers high T1 relaxivity.

Authors:  Zijian Zhou; Rong Hu; Lirong Wang; Chengjie Sun; Gang Fu; Jinhao Gao
Journal:  Nanoscale       Date:  2016-10-20       Impact factor: 7.790

Review 3.  Manganese-based hollow nanoplatforms for MR imaging-guided cancer therapies.

Authors:  Shuang Liang; Guangfu Liao; Wenzhen Zhu; Li Zhang
Journal:  Biomater Res       Date:  2022-07-06

4.  Renal-clearable hyaluronic acid functionalized NaGdF4 nanodots with enhanced tumor accumulation.

Authors:  Yining Yan; Lei Ding; Lin Liu; Murad M A Abualrejal; Hongda Chen; Zhenxin Wang
Journal:  RSC Adv       Date:  2020-04-06       Impact factor: 4.036

5.  Hybrid Core-Shell (HyCoS) Nanoparticles produced by Complex Coacervation for Multimodal Applications.

Authors:  D Vecchione; A M Grimaldi; E Forte; Paolo Bevilacqua; P A Netti; E Torino
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

6.  Multimodal Imaging Nanoparticles Derived from Hyaluronic Acid for Integrated Preoperative and Intraoperative Cancer Imaging.

Authors:  William M Payne; Tanner K Hill; Denis Svechkarev; Megan B Holmes; Balasrinivasa R Sajja; Aaron M Mohs
Journal:  Contrast Media Mol Imaging       Date:  2017-09-11       Impact factor: 3.161

Review 7.  Nanoparticle-Based Paramagnetic Contrast Agents for Magnetic Resonance Imaging.

Authors:  Juan Pellico; Connor M Ellis; Jason J Davis
Journal:  Contrast Media Mol Imaging       Date:  2019-05-05       Impact factor: 3.161

8.  Polyol-Made Luminescent and Superparamagnetic β-NaY0.8Eu0.2F4@γ-Fe2O3 Core-Satellites Nanoparticles for Dual Magnetic Resonance and Optical Imaging.

Authors:  Walid Mnasri; Lotfi Ben Tahar; Patricia Beaunier; Darine Abi Haidar; Michel Boissière; Olivier Sandre; Souad Ammar
Journal:  Nanomaterials (Basel)       Date:  2020-02-23       Impact factor: 5.076

Review 9.  Iron-Based Hollow Nanoplatforms for Cancer Imaging and Theranostics.

Authors:  Shun Luo; Shuijie Qin; Gerile Oudeng; Li Zhang
Journal:  Nanomaterials (Basel)       Date:  2022-08-31       Impact factor: 5.719

10.  Dual Imaging Gold Nanoplatforms for Targeted Radiotheranostics.

Authors:  Francisco Silva; António Paulo; Agnès Pallier; Sandra Même; Éva Tóth; Lurdes Gano; Fernanda Marques; Carlos F G C Geraldes; M Margarida C A Castro; Ana M Cardoso; Amália S Jurado; Pilar López-Larrubia; Sara Lacerda; Maria Paula Cabral Campello
Journal:  Materials (Basel)       Date:  2020-01-22       Impact factor: 3.623

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.